Webinar on Collaborative Communities: October 29, 2019
The FDA hosted a webinar to share information and answer questions about collaborative communities and the final version of the Collaborative Communities Toolkit.
In the medical device ecosystem, collaborative communities bring together stakeholders to achieve common outcomes, solve shared challenges, and leverage collective opportunities. CDRH believes collaborative communities can contribute to improvements in areas affecting patients and health care in the United States. Accordingly, participation in collaborative communities is one of CDRH's strategic priorities for 2018-2020.
CDRH encourages interested stakeholders to learn more about collaborative communities and review the toolkit, which provides a collection of helpful ideas to foster strong collaborative communities that are well-prepared to take on health care challenges.
On this page:
- What Is a Collaborative Community?
- Members of a Collaborative Community
- Considerations for CDRH Participation in a Collaborative Community
- Collaborative Communities with CDRH Participation
- Collaboration Communities Toolkit
- Examples of Collaborative Communities in Other Sectors
- Frequently Asked Questions
A collaborative community is a continuing forum in which private- and public-sector members, which can include the FDA, work together on medical device challenges to achieve common objectives and outcomes. They are convened by interested stakeholders and may exist indefinitely, produce deliverables as needed, and tackle challenges with broad impacts. Collaborative communities may develop for a number of reasons, including when:
- Challenges are ill-defined or there is no consensus on the definition of the challenges
- Challenges and outcomes are complex
- Partners are interrelated
- Incremental or unilateral efforts to address the challenge have been ineffective
- Partners seek to optimize efforts, including preventing duplication of efforts
- Better outcomes could be achieved with integrating different perspectives, experiences, resources, and expertise.
For more information: Fostering Collaborative Communities to Improve Patient Healthcare (FDA Voices, December 4, 2018)
Collaborative communities typically include diverse, relevant organizations and individuals impacted by a specific topic. For example, patients and care-partners, academics, health care professionals, payers, federal and state agencies, international regulatory bodies, and industry may be engaged as part of a collaborative community.
Members of a collaborative community may represent many types of medical device stakeholders. The Collaborative Communities Toolkit provides more information on community membership.
Established collaborative communities may wish to invite CDRH to participate. CDRH's decision to participate as a member is influenced by the public health impact of the community, its alignment with CDRH's regulatory mission, current priorities and resources. CDRH makes participation decisions on a case-by-case basis and may consider whether the community has a governance structure, a convener, a plan to measure success and a mechanism for sustained engagement to help determine whether CDRH will participate.
The FDA currently participates as a member of the following collaborative communities, which have been established and are managed and controlled by external stakeholders.
- Ophthalmic Imaging Collaborative Community
- National Evaluation System for health Technology Coordinating Center (NESTcc) Collaborative Community
The Collaborative Communities Toolkit is a collection of materials that could help prospective communities in their development and effective collaboration, so that they are adequately prepared to take on health care challenges.
Each component of this toolkit could help members of both new and existing communities work with one another.
Collaborative communities have been created to tackle challenges in other sectors.
Challenge: Underage drinking resulting in many complaints of noise, vandalism, and other crimes in a college town. Community police and the college's efforts failed to mitigate the problem.
Collaborators: College, State Liquor Commission Enforcement Office, local police, property owners, and students.
Description: Multiprong solution involved revised student orientation to cover underage drinking, monitoring of stores selling to minors by the State Liquor Enforcement Office, increased officer presence during peak drinking hours, informing property owners of legal consequences of underage drinking, and increased enforcement in nightclubs. The activity needed to be sustained to ensure long-term lasting effects and tailored to adapt to the changing landscape. Calls for service to off-campus residences for underage drinking were reduced by 50-70 percent.
Reference: TA Rinehart, AT Laszlo, and GO Briscoe. Collaboration Toolkit: How to Build, Fix, and Sustain Productive Partnerships. Washington, DC: US Department of Justice, Office of Community Oriented Policing Services, 2001. Available at https://www.hsdl.org/?view&did=454094 (accessed September 19, 2019).
Challenge: High infant mortality in Washington, DC, which exceeds that of most states and is higher than infant mortality in New York City or Los Angeles.
Collaborators: Health care providers, government agencies and social service providers, community-based organizations, hospital systems, patients with lived experience, housing, transportation, and potential employers.
Description: The DC Community Action Network uses shared measurement systems (establishing how success will be measured and reported); mutually reinforcing activities (ensuring each participant is doing activities within their expertise and that are coordinated with other participants' activities); continuous communication (helping to develop trust among organizations that are not used to working with each other and keeping partners engaged); and DC Health (allowing DC Health to provide some of the infrastructure for coordination). Research is currently underway to learn more about health practices of pregnant women in Washington.
Reference: District of Columbia Department of Health: Perinatal Health and Infant Mortality Report. May 2018. Available at https://bit.ly/2NHwWOG (accessed September 19, 2019).
Does the FDA establish collaborative communities?
Answer: No. The FDA does not establish, manage, or control collaborative communities. As such, the FDA does not decide the membership, schedule meetings or set agendas, or control the community's operations. Collaborative communities can exist without the FDA's participation.
What roles can FDA staff assume in a collaborative community?
Answer: An FDA staff member can participate as a member of a collaborative community in a manner similar to that of other members. However, an FDA staff member cannot chair or convene the collaborative community. FDA staff members may participate in workstreams, as well as lend a regulatory perspective to discussions.
Are collaborative communities an alternative to standards, federal advisory committees, or other established regulatory processes?
Answer. No. Collaborative communities do not replace established regulatory mechanisms. The FDA will follow good guidance practices, ethics, standards, and other existing process for conducting its business. The FDA's participation in collaborative communities must comport with these existing obligations. A collaborative community is not a federal advisory committee. For more information on the FDA's advisory committees, see About Advisory Committees.
If you have questions about collaborative communities, or if you have a collaborative community in which you would like the FDA to participate, email CDRHCollabCommunities@fda.hhs.gov.